12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Reolysin: Additional Phase II data

Oncolytics reported data from 21 evaluable chemotherapy-naïve patients with metastatic or recurrent SCC of the lung in the 2-stage, open-label, U.S. Phase II REO 021 trial showing that IV Reolysin plus paclitaxel and carboplatin met the primary endpoint of an ORR of >=35%. Specifically, Reolysin plus paclitaxel and carboplatin led to an ORR of 42.8%, including 9 partial responses (PR) plus 9 cases...

Read the full 291 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >